Q3 2026 Agilent Technologies Inc Earnings Call Transcript
Key Points
- Agilent Technologies Inc (A) delivered strong Q3 FY2026 results with core revenue growth of 7.3%, exceeding guidance by 140 basis points, and EPS of $1.56 (ex-refunds) growing 14% year-over-year.
- The company's Ignite transformation program is driving significant operational efficiencies, leading to a 210 basis point year-over-year operating margin expansion (ex-tariff refunds) and over 100 basis points of full-year margin expansion expected.
- Pharma end market grew 12% in Q3, driven by strong GLP-1 momentum (70% growth) and a nearly 30% growth in the Advanced Therapeutics CDMO business, with a robust order book for future capacity.
- China showed a notable recovery, growing 9% in Q3 versus flat expectations, driven by strong execution in pharma and food, with momentum expected to continue into year-end.
- New product launches (9500 ICP-MS, 8890B/8860B GCs, Altura columns) are off to a strong start, with orders exceeding expectations and a $60 million funnel for the 9500, supporting future growth.
- The company raised its full-year guidance for core revenue growth to 5.8%-6% and EPS to $6.18-$6.21 (including tariff refunds), reflecting confidence in continued momentum.
- Pharma reshoring is beginning to materialize, with initial orders booked from five of the top 10 global pharma companies in Q3, supporting a multi-year growth opportunity.
- Strong cash flow generation with operating cash flow of $519 million and free cash flow conversion of 96% in Q3, maintaining a solid balance sheet with net leverage of 1 turn.
- The company's Q4 FY2026 guidance implies a slowdown in core growth to 5.2%-6.2%, partly due to a tough comparison in the Advanced Therapeutics business, which is expected to be flattish.
- The Diagnostics and Clinical end market grew 6% in Q3, slightly below the high-single-digit guide, despite robust double-digit order growth, indicating some revenue timing issues.
- The Academic and Government end market declined 3% in Q3, below expectations, with continued softness in China and funding shifts toward defense.
- The company faces ongoing inflationary pressures from the Middle East conflict and memory chip demand, which could impact costs, though partially mitigated by Ignite efficiencies.
- Europe grew only low single-digits in Q3, with pharma growth of low single-digits against a tough compare, and the company expects low single-digit growth for the full year in the region.
- The Chemical and Energy (C&E) sub-segment within Applied Markets grew only low single-digits in Q3, with softness in refining and geopolitical disruptions in EMEA, though overall CAM grew 7%.
- The company's Q4 guidance does not include any future benefit from potential tariff refunds, which could create a headwind to EPS growth in the quarter.
- The specialty CDMO business faces a flattish Q4 due to timing of regulatory submissions, and the ramp-up of Train C will involve hiring and depreciation costs before revenue generation, potentially pressuring margins.
Ladies and gentlemen, thank you for joining us and welcome to the Q3 2026 Agilent Technologies Inc earnings conference call. (Operator Instructions) I will now hand the call over to Tejas Savant, Head of Investor Relations. You may begin.
Thank you, and welcome, everyone, to Agilent's conference call for the third quarter of fiscal year 2026. With me on the line are CEO, Padraig McDonnell; and CFO, Adam Elinoff. Joining for the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group; Angelica Riemann, President of the Agilent CrossLab Group; and Mike Zhang, President of the Applied Markets Group.
This presentation is being webcast live. The press release for our third quarter financial results, investor presentation and information to supplement today's discussion, along with the recording of this webcast, are available on our website at investor.agilent.com.
Today's comments will refer to non-GAAP financial measures. Non-GAAP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
